Jerzy P Szaflarski, Hervé Besson, Wendyl D'Souza, Edward Faught, Pavel Klein, Markus Reuber, Felix Rosenow, Javier Salas-Puig, Victor Soto Insuga, Bernhard J Steinhoff, Adam Strzelczyk, Dimitrios Bourikas, Tony Daniels, Florin Floricel, David Friesen, Cédric Laloyaux, Vicente Villanueva
OBJECTIVE: To assess the effectiveness and tolerability of brivaracetam (BRV) in adults with epilepsy by specific comorbidities and epilepsy etiologies. METHODS: EXPERIENCE/EPD332 was a pooled analysis of individual patient records from several non-interventional studies of patients with epilepsy initiating BRV in clinical practice. Outcomes included ≥ 50% reduction from baseline in seizure frequency, seizure freedom (no seizures within prior 3 months), continuous seizure freedom (no seizures since baseline), BRV discontinuation, and treatment-emergent adverse events (TEAEs) at 3, 6, and 12 months...
March 4, 2024: Journal of Neurology